Kimberly Gentile
Chief Tech/Sci/R&D Officer en BIOHAVEN LTD. .
Fortuna: 5 M $ al 31/03/2024
Cargos activos de Kimberly Gentile
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
BIOHAVEN LTD. | Chief Tech/Sci/R&D Officer | - | - |
Portage Pharmaceutical Ltd.
Portage Pharmaceutical Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Juvenescence Ltd., Portage Pharmaceutical Ltd. is a research and developer of biotechnology pharmaceutical drugs. The private company is based in Toronto, Canada. Portage Pharmaceutical was acquired by Juvenescence Ltd. from Portage Biotech, Inc. on March 04, 2021 for $193.25 million. The CEO of the Canadian company is Frank W. Marcoux. | Chief Operating Officer | - | - |
Historial de carrera de Kimberly Gentile
Antiguos cargos conocidos de Kimberly Gentile.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Director/Board Member | - | 03/10/2022 |
Corporate Officer/Principal | 01/02/2014 | 03/10/2022 | |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2000 | 01/02/2014 |
SCIREX Corp. | Corporate Officer/Principal | 01/01/1996 | 01/06/2000 |
Formación de Kimberly Gentile.
Salem State University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 4 |
Canadá | 2 |
Operativa
Corporate Officer/Principal | 3 |
Director/Board Member | 1 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 4 |
Commercial Services | 3 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
BIOHAVEN LTD. | Health Technology |
Empresas privadas | 3 |
---|---|
SCIREX Corp. | Commercial Services |
Biohaven Pharmaceutical Holding Co. Ltd.
Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Portage Pharmaceutical Ltd.
Portage Pharmaceutical Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Juvenescence Ltd., Portage Pharmaceutical Ltd. is a research and developer of biotechnology pharmaceutical drugs. The private company is based in Toronto, Canada. Portage Pharmaceutical was acquired by Juvenescence Ltd. from Portage Biotech, Inc. on March 04, 2021 for $193.25 million. The CEO of the Canadian company is Frank W. Marcoux. | Commercial Services |
- Bolsa de valores
- Insiders
- Kimberly Gentile
- Experiencia